RxDoctor Payments Data

Lynette Moore, NP

Psychiatric/Mental Health · Montrose, CONPI 1457369688

Payments from drug & device makers

$1,104in general payments, 2019–2025

Across 29 payments — averaging $38.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$398
  • Otsuka America Pharmaceutical, Inc.$177
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
  • Neurocrine Biosciences, Inc.$141
  • Alkermes, Inc.$127
  • Lundbeck LLC$58
  • plus $53 from 2 others

What the payments were for

  • Food & beverage$1,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,104 in reported general payments places this provider in the 75th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Medicare billing

Part B allowed, 2024
$8,065
Medicare patients
31
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$137,521
AustedoDeutetrabenazine11$76,324
Invega SustennaPaliperidone Palmitate13$24,836
RexultiBrexpiprazole13$19,666
Clozapine93$3,497
Quetiapine Fumarate151$2,324
Ziprasidone Hcl15$1,801
Lurasidone Hcl55$1,638
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$1,632
Atomoxetine Hcl14$1,546
Aripiprazole86$1,437
Paliperidone ErPaliperidone16$1,414
Buspirone Hcl91$1,295
Risperidone95$1,133
Venlafaxine Hcl ErVenlafaxine Hcl54$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$141$137,52115 claims
Johnson & JohnsonInvega Sustenna$398$24,83613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$177$19,66613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Montrose

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →